Patents by Inventor Akira Shimamoto
Akira Shimamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8809296Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: GrantFiled: September 27, 2012Date of Patent: August 19, 2014Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20140179769Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8703930Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: May 22, 2013Date of Patent: April 22, 2014Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Publication number: 20140064174Abstract: A wireless communication system includes a user terminal capable of discontinuous reception (DRX) and a base station communicating with the user terminal. The user terminal includes a receiving section for receiving information about DRX from the base station; a DRX cycle setting section for setting DRX cycles; a first period setting section for setting a first period among the DRX cycles to receive a downlink signal; and a receivable period setting section for setting a receivable period to receive the downlink signal within a second period outside of the first period. The base station includes a DRX cycle setting section for setting the DRX cycles; a first period setting section for setting the first period; a receivable period setting section for setting the receivable period; and a transmission section for transmitting the set information to the user terminal to be set on the user terminal.Type: ApplicationFiled: November 13, 2013Publication date: March 6, 2014Applicant: FUJITSU LIMITEDInventors: Masahiro ABE, Akira SHIMAMOTO, Takato EZAKI
-
CANCER CELL-SPECIFIC APOPTOSIS-INDUCING AGENTS THAT TARGET CHROMOSOME STABILIZATION-ASSOCIATED GENES
Publication number: 20130245097Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: May 22, 2013Publication date: September 19, 2013Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8470798Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: May 16, 2012Date of Patent: June 25, 2013Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Patent number: 8314073Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: GrantFiled: November 17, 2005Date of Patent: November 20, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Patent number: 8299044Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: GrantFiled: December 21, 2009Date of Patent: October 30, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
CANCER CELL-SPECIFIC APOPTOSIS-INDUCING AGENTS THAT TARGET CHROMOSOME STABILIZATION-ASSOCIATED GENES
Publication number: 20120225928Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: Genecare Research Instiute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8193332Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: April 8, 2005Date of Patent: June 5, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Publication number: 20100168209Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: ApplicationFiled: December 21, 2009Publication date: July 1, 2010Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20090215867Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: ApplicationFiled: November 17, 2005Publication date: August 27, 2009Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Publication number: 20090028861Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: April 8, 2005Publication date: January 29, 2009Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Patent number: 7329497Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: GrantFiled: May 2, 2006Date of Patent: February 12, 2008Assignee: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20070243570Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: ApplicationFiled: May 19, 2004Publication date: October 18, 2007Applicant: Genecare Research Institute Co., LtdInventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20060240470Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: June 30, 2006Publication date: October 26, 2006Applicant: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20060188928Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: May 2, 2006Publication date: August 24, 2006Applicant: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Patent number: 7081522Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: GrantFiled: January 19, 2000Date of Patent: July 25, 2006Assignee: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20040259147Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: July 2, 2004Publication date: December 23, 2004Applicant: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20040224312Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: December 31, 2001Publication date: November 11, 2004Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi